Acticor Biotech Repositions Glenzocimab for Myocardial Infarction Treatment
• Acticor Biotech is focusing on myocardial infarction with glenzocimab, encouraged by expert feedback on its potential in STEMI treatment.
• The LIBERATE phase 2b study, in partnership with the University of Birmingham, is ongoing, assessing glenzocimab's impact on infarct size in 212 STEMI patients.
• A new phase 2 study, GLORIA, is being prepared to evaluate glenzocimab in approximately 300 STEMI patients, aiming for Phase 3 readiness by 2027.
• Patient recruitment for GLORIA could begin in Q1 2025, contingent on the company's financial status and ongoing receivership procedure.
© Copyright 2025. All Rights Reserved by MedPath